Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Subscribe to see Bicara Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Bicara Therapeutics Inc. is a biotechnology company headquartered in Boston, United States. It is publicly listed (BCAX) with a market capitalisation of $1.2B. Xcout tracks 23 named people at Bicara Therapeutics Inc., including Claire Mazumdar Clemon (Chief Executive Officer & Director). Xcout recorded 17 job postings from Bicara Therapeutics Inc. in the last 90 days, naming tools such as NetSuite, Workday.
17 more named people on record for Bicara Therapeutics Inc., with roles, board committees and tenure — see the full roster →
Xcout recorded 17 job postings from Bicara Therapeutics Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Bicara Therapeutics Inc.'s hiring signals →
A few of Bicara Therapeutics Inc.'s closest competitors — see the full list of competitors and alternatives →
Hiba Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts, United States, advancing a targeted approach through its TROIKA platform to activate tumor-resident T cells.
Ankyra Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2019 and headquartered in Cambridge, Massachusetts. The enterprise specializes in developing proprietary anchored cytokine therapies designed to treat various cancers and immune diseases. Its platform technology localizes immune-stimulatory treatments within tumors to maximize therapeutic efficacy while minimizing systemic toxicity.
HiFiBio Therapeutics is a clinical-stage immune modulation biotechnology company headquartered in Cambridge, Massachusetts. The company focuses on discovering and developing novel precision antibody therapeutics for immunology and oncology applications.
KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies designed to target and block tumor suppression.
Boston Immune Technologies and Therapeutics, Inc. (BITT) is a company headquartered in Winchester, Massachusetts, that specializes in the development of cancer treatments and therapeutics.
Veraxa Biotech AG discovers and develops next-generation antibody-based cancer therapeutics, including antibody-drug conjugates (ADCs) and novel antibody formats. The company utilizes proprietary technologies such as BiTAC and functional antibody screening to build a therapeutic pipeline aimed at improving patient safety and treatment efficacy.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Bicara Therapeutics Inc.? Suggest a correction
Post the link and the card appears automatically — each network fetches the image itself.